Results for this period
First quarter1 November 2025 to 31 January 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
The number of contracts for the core blood-derived processing services and adipose-derived stem cell processing services increased, while costs were reduced mainly in selling, general and administrative expenses. Medical device sales received no orders from major customers in January, and cosmetics sales declined under the B2B model.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 November 2025 to 31 January 2026 |
| Net Sales | ¥860 million (YoY +1.3%) |
| Operating profit | ¥59 million |
| Ordinary income | ¥59 million |
| Profit attributable to owners of the parent | ¥33 million |
| Net income per share | JPY 1.70 |
| Equity ratio | End of the current fiscal period 84.7 / End of previous period 84 |
| Total assets | ¥6,892 million |
| Net assets | ¥5,950 million |
| Full-year earnings forecast | Net Sales ¥3,418 million (YoY -7.9%) / Operating profit ¥-170 million / Ordinary income ¥-164 million / Net income ¥-136 million |
| Annual Dividend Forecast | ¥5 → ¥0 |
| Depreciation and amortization | ¥43,732 thousand |
| Impairment loss | ¥11,665 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on reversal of subscription rights to shares ¥2,916 thousand / Extraordinary loss Impairment Losses ¥11,665 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 19,827,162 shares |
| Treasury Shares at Period-End | 580 shares |
| Factors Behind Changes in Business Performance | The number of contracts for the core blood-derived processing services and adipose-derived stem cell processing services increased, while costs were reduced mainly in selling, general and administrative expenses. Medical device sales received no orders from major customers in January, and cosmetics sales declined under the B2B model. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The number of contracts for blood-derived processing services and adipose-derived stem cell processing services increased from the previous fiscal year. The Company also continued to optimize the allocation of management resources and reduce costs, mainly in selling, general and administrative expenses.